<DOC>
	<DOC>NCT00958893</DOC>
	<brief_summary>An open label, extension study for subjects completing the ZPU-003 Ext 1 study.</brief_summary>
	<brief_title>An Extension Study Evaluating Safety and Efficacy of Proellex® In Women Who Have Previously Completed ZPU 003 Ext</brief_title>
	<detailed_description>This is an open label, extension study for subjects completing the ZPU-003 Ext 1 study and an off-drug interval (menses), prior to the start of the first 16-week dosing cycle. Subjects will receive a 50 mg Proellex® daily dose. Total study participation for ZPU-003 Ext 2 (Extension 2) may be up to three 4 month drug cycles separated by off drug intervals.</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>Four subjects at one site whom have completed ZPU 003 Ext 1 study All other subjects</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Uterine fibroids</keyword>
</DOC>